Research Papers:
Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3198 views | HTML 3354 views | ?
Abstract
Nai-si Huang1,2,*, Ya-yun Chi1,2,*, Jing-yan Xue1,2, Meng-ying Liu1,2, Sheng Huang1,2, Miao Mo2,3, Shu-ling Zhou2,4, Jiong Wu1,2,5
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, China
2Department of Oncology, Shanghai Medical College, Fudan University, China
3Department of Clinical Statistics, Fudan University Shanghai Cancer Center, China
4Department of Pathology, Fudan University Shanghai Cancer Center, China
5Collaborative Innovation Center of Cancer Medicine, China
*These authors contributed equally to this work
Correspondence to:
Jiong Wu, email: [email protected]
Keywords: MALAT1, long non-coding RNA, breast cancer, estrogen receptor
Received: March 07, 2016 Accepted: April 27, 2016 Published: May 13, 2016
ABSTRACT
Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1), a lncRNA that was first recognized as a prognostic parameter for patient survival of stage I lung cancer, is up-regulated in multiple human malignancies, including breast cancer. However, the mechanism of its function remained elusive. In the current study, by examining MALAT1 expression on mRNA level, we demonstrated that compared with MCF10A, MALAT1 expression was up-regulated in the majority of breast cancer cell lines (9/12). In 26 pairs of estrogen receptor (ER)-positive breast cancer samples, MALAT1 expression was significantly up-regulated compared with adjacent normal tissues (P = 0.012). Furthermore, of 204 breast cancer patients, high MALAT1 expression was associated with positive ER (P = 0.023) and progesterone receptor (PR) (P = 0.024) status. Further analysis using TCGA database revealed that ER and its target genes PGR and CCND1, were overexpressed in MALAT1 altered group compared with unaltered group, both on the mRNA and protein level. Lastly, we verified MALAT1’s prognostic value in breast cancer. At the cut-off value of 75%, MALAT1 was the only independent prognostic factor of recurrence-free survival (RFS) in ER-negative patients in a multivariate Cox regression model (hazard ratio [HR] = 2.83, 95% confidence interval [CI] 1.02–7.83). MALAT1 overexpression was also associated with poor RFS in tamoxifen treated ER-positive breast cancer patients, which might serve as a potential biomarker to predict endocrine treatment sensitivity.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9364